Asahi Kasei (AHKSF) faces challenges from trade tensions and macroeconomic pressures. Read why I remain neutral on the stock.

Asahi Kasei has a 12-month low of $12.14 and a 12-month high of $15.80. The company has a quick ratio of 0.99, a current ratio of 1.69 and a debt-to-equity ratio of 0.43.

Under Shinomiya’s leadership, Asahi Kasei’s Healthcare Sector will further advance its portfolio and global presence.

Asahi Kasei Life Science expects to offer the bioindustry more agile and focused services and deeper innovation in bioprocess solutions.

Asahi Kasei stock opened at $13.29 on Thursday. Asahi Kasei has a 1-year low of $12.12 and a 1-year high of $15.80. The business has a fifty day moving average price of $13.70 and a 200-day moving ...

As part of the evolving pharmaceutical ecosystem, where multiple stakeholders are involved in drug development and manufacturing, Asahi Kasei’s bioprocess-related business units have operated ...

Leading the way for the sector’s continued growth and commitment to improving patient outcomes Asahi Kasei has appointed Ken Shinomiya, President of Asahi Kasei Life Science, as the Leader of ...

TOKYO & NOVI, Mich., & DÜSSELDORF, Germany, April 08, 2025--(BUSINESS WIRE)--To meet growing demand from the pharmaceutical industry, Asahi Kasei has established Asahi Kasei Life Science to ...

CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--Asahi Kasei has appointed Ken Shinomiya, President of Asahi Kasei Life Science, as the Leader of its Healthcare ...